The potency of exendin-4 (log EC 50 value, -9.710.21) was slightly stronger than that of human GLP-1 (log EC 50 value, -9.200.11) and xGLP (log EC 50 value, -9.080.12)
tirzepatida no se maneja como un ciclo corto, sino como una intervencin de mantenimiento que se revisa y ajusta de manera peridica con base en metas clnicas
Your provider should discuss realistic expectations: GLP-1 may not cause significant weight loss in non-overweight patients, but benefitsimproved glucose control, cardiovascular protection, reduced inflammationremain clinically meaningful
Mean SD CRLB for glutamate, GSH, and GABA were 2.0 0%, 5.0 0.8%, and 8.3 1.6%, respectively